We have developed a new preclinical mouse model that will help the lung cancer community to develop and test in vivo novel therapeutic options for patients with EGFR-mutated lung cancer who relapse after osimertinib therapy due to the appearance of MET amplification. Here, MET is linked to lung carcinoma.